![Charlotte Keywood](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Charlotte Keywood
Keine laufenden Positionen mehr
Profil
Dr. Charlotte Keywood is Chief Medical Officer-Therapeutics Division at Amarantus Bioscience Holdings, Inc.
Dr. Keywood was previously employed as Chief Medical Officer by Addex Therapeutics Ltd., Medical Director by Axovan AG, and Medical Director by British Biotech Plc.
Ehemalige bekannte Positionen von Charlotte Keywood
Unternehmen | Position | Ende |
---|---|---|
Axovan AG
![]() Axovan AG Miscellaneous Commercial ServicesCommercial Services Axovan AG conducts biopharmaceutical research and develops pharmaceuticals. Active in pharmaceutical research and development, it focuses on the family of drug targets called G protein-coupled receptors (GPCRs), which are involved in a number of pathologies. It has developed a validated GPCR-based chemical library through its proprietary chem-informatics platform AXADDIS. Its lead product, clasozentan, is an intravenous endothelin receptor antagonist optimized for treating cerebral diseases. It is partnering non-core indication projects (pain, metabolic diseases, inflammation) at earlier stages. The company was founded in 2000 and is headquartered in Allschwil, Switzerland. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2003 |
VERNALIS | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2001 |
ADDEX THERAPEUTICS LTD | Technik-/Wissenschafts-/F&E-Leiter | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ADDEX THERAPEUTICS LTD | Health Technology |
Private Unternehmen | 2 |
---|---|
Axovan AG
![]() Axovan AG Miscellaneous Commercial ServicesCommercial Services Axovan AG conducts biopharmaceutical research and develops pharmaceuticals. Active in pharmaceutical research and development, it focuses on the family of drug targets called G protein-coupled receptors (GPCRs), which are involved in a number of pathologies. It has developed a validated GPCR-based chemical library through its proprietary chem-informatics platform AXADDIS. Its lead product, clasozentan, is an intravenous endothelin receptor antagonist optimized for treating cerebral diseases. It is partnering non-core indication projects (pain, metabolic diseases, inflammation) at earlier stages. The company was founded in 2000 and is headquartered in Allschwil, Switzerland. | Commercial Services |
Ligand UK Ltd.
![]() Ligand UK Ltd. Pharmaceuticals: MajorHealth Technology Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1988 and is headquartered in Winnersh, the United Kingdom. | Health Technology |